DCK

DCK TOOLS Celebrates 29 Years of Industry Excellence at National Hardware Show 2024

Retrieved on: 
星期四, 三月 28, 2024
Partnership, Safety, National Hardware Show, Research, NHS, DCK

LAS VEGAS, March 28, 2024 /PRNewswire/ -- DCK TOOLS (DongCheng company), a trusted supplier and innovator of professional power tools made its first appearance at the National Hardware Show (NHS) 2024 held in Las Vegas.

Key Points: 
  • LAS VEGAS, March 28, 2024 /PRNewswire/ -- DCK TOOLS (DongCheng company), a trusted supplier and innovator of professional power tools made its first appearance at the National Hardware Show (NHS) 2024 held in Las Vegas.
  • As the company's debut at the NHS and its inaugural tradeshow in the U.S., DCK TOOLS showcased its diverse range of cordless power tools, electric tools, cordless outdoor power equipment, and more.
  • Despite the saturated and diverse power tools market, many professionals consistently favor DCK TOOLS for demanding worksites.
  • Found in 1995, DCK TOOLS (DongCheng company) has dedicated research and manufacturing centers that continue to innovate and ensure quality.

DCK ELEVATES BILL BROWN TO PRESIDENT

Retrieved on: 
星期三, 一月 17, 2024
Arena, DCK, Management

MIAMI, Jan. 17, 2024 /PRNewswire/ -- DCK Worldwide Group, LLC ("DCK"), a 102-year-old US-based construction management firm, proudly announces the promotion of Bill Brown to the position of President, effective immediately.

Key Points: 
  • MIAMI, Jan. 17, 2024 /PRNewswire/ -- DCK Worldwide Group, LLC ("DCK"), a 102-year-old US-based construction management firm, proudly announces the promotion of Bill Brown to the position of President, effective immediately.
  • Bill has been an invaluable contributor to DCK since joining the firm in 2021, consistently demonstrating exemplary leadership, strategic vision, and a deep understanding of the construction landscape.
  • Since joining DCK, Bill has consistently demonstrated outstanding leadership, innovative thinking, and a deep understanding of the unique challenges and opportunities presented by DCK's key customer markets.
  • These capital markets capabilities are a further differentiator in the full range of solutions DCK offers for complex construction projects.

Introducing DexCheck: The Future of AI-Enhanced Analytics in Crypto and NFT Markets

Retrieved on: 
星期一, 五月 22, 2023
VCS, Blockchain, IDO, NFT, Non-fungible token, DCK, News, Social media, Machine learning, Cryptocurrency

By offering advanced data analytics, DexCheck is not just keeping pace with the market, but setting the stage for the future of blockchain analytics.

Key Points: 
  • By offering advanced data analytics, DexCheck is not just keeping pace with the market, but setting the stage for the future of blockchain analytics.
  • "Typically, advanced analytics in the crypto and NFT markets are reserved for VCs and professional investors with large budgets.
  • This truly democratizes access to high-level analytics and insights in the crypto and NFT markets.”
    DexCheck's unique offering centers on AI-enhanced analytics, which harness the power of machine learning and big data to provide actionable insights for users.
  • DexCheck invites potential investors to take part in shaping the future of crypto and NFT analytics and to reap the benefits of this rapidly growing sector.

Trethera Announces Poster Presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Retrieved on: 
星期二, 一月 24, 2023
Treatment, Visual impairment, Great America Committee, Research, MS, Cancer, Multiple sclerosis, CD4, University of California, Los Angeles, University, Patient, DCK, Degenerative disease, Brain, Optic neuritis, Optic nerve, Medical imaging

LOS ANGELES, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces an upcoming poster presentation at the 8th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS).

Key Points: 
  • LOS ANGELES, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces an upcoming poster presentation at the 8th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS).
  • Dr. Peter M. Clark, of the University of California Los Angeles, will present preclinical research highlighting the use of Trethera’s deoxycytidine kinase (dCK) inhibitor, TRE-515, that suggests a functional role for deoxyribonucleoside salvage and dCK in multiple sclerosis (MS) mouse models.
  • Figure 1: PET scans showing mouse brain before (left) and after (right) MS induction (brain encircled in a dashed white line).
  • Targeting dCK with first-in-class inhibitor TRE-515 is shown to block symptoms across multiple MS mouse models by specifically limiting activated B and CD4 T cell proliferation.

Trethera Announces Multiple Sclerosis Treatment Poster Presentation at the American Neurological Association Annual Meeting

Retrieved on: 
星期二, 十月 4, 2022
Orphan drug, ANA, Cancer, GLOBE, Acute disseminated encephalomyelitis, Optic nerve, American Neurological Association, Immunology, Adult, Nucleotide, MS, EAE, Research, Private Securities Litigation Reform Act, DCK, Deoxycytidine kinase, FDA, University of California, Los Angeles, Autoimmunity, COVID-19, Visual impairment, UCLA, Lists of diseases, ADEM, Degenerative disease, Patient, Multiple sclerosis, Optic neuritis, Central nervous system, University, DNA, Company, Pharmaceutical industry

LOS ANGELES, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (Trethera), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces an upcoming poster presentation at the 147th Annual Meeting of the American Neurological Association (ANA).

Key Points: 
  • LOS ANGELES, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (Trethera), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces an upcoming poster presentation at the 147th Annual Meeting of the American Neurological Association (ANA).
  • The ANA meeting is one of the largest annual gatherings of MS researchers and a key venue for presenting noteworthy neurology discoveries.
  • The work presented by Dr. Clark also has application for optic neuritis, a rare neurologic disease which affects the optic nerve causing visual impairment.
  • TRE-515 is an orally delivered first-in-class therapeutic engineered to inhibit dCK, the key enzyme in the nucleoside salvage pathway.

U.S. Patent Office Issues Trethera Composition of Matter Patent Covering TRE-515, Extending Market Exclusivity to Late 2041

Retrieved on: 
星期二, 九月 20, 2022
Multiple sclerosis, Deoxycytidine kinase, FDA, COVID-19, DCK, Company, Private Securities Litigation Reform Act, UCLA, Patient, Cancer, USPTO, United States Patent and Trademark Office, Patent, CT, Degenerative disease, Method, Research, DNA, GLOBE, Orphan drug, Wilson Sonsini Goodrich & Rosati, Pharmaceutical industry

The resulting US patent extends the patent protection for TRE-515 in the United States by at least seven years through November 2041.

Key Points: 
  • The resulting US patent extends the patent protection for TRE-515 in the United States by at least seven years through November 2041.
  • We are extremely pleased with this addition to the TRE-515 patent portfolio, said Dr. Ken Schultz, Trethera CEO and patent co-inventor.
  • Succeeding in this patent application demonstrates Tretheras strong overall commitment to protecting the innovation and commercialization of our lead asset.
  • Trethera is currently enrolling a Phase 1 dose escalation trial to evaluate TRE-515 monotherapy in patients with various solid tumors.

Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control and Improve Multiple Sclerosis Symptoms in Mouse Models

Retrieved on: 
星期三, 九月 7, 2022
Molecular imaging, PET, ADEM, Cancer, Research, Time of flight, Degenerative disease, Brain, Deoxycytidine kinase, Science, Multiple sclerosis, DCK, CyTOF, Pediatrics, DNA, EAE, Orphan drug, National, Immunology, GLOBE, National academy, Cytometry, Company, FDA, Stanford University, UCLA, MS, COVID-19, Optic neuritis, Private Securities Litigation Reform Act, Patient, Pharmaceutical industry, Medical imaging

TRE-515 is a clinical stage drug being developed by Trethera that targets the enzyme deoxycytidine kinase (dCK) in the deoxyribonucleoside salvage pathway.

Key Points: 
  • TRE-515 is a clinical stage drug being developed by Trethera that targets the enzyme deoxycytidine kinase (dCK) in the deoxyribonucleoside salvage pathway.
  • Their results demonstrated that dCK activity is necessary for the development of clinical symptoms in both EAE models of MS.
  • Targeting dCK with TRE-515 limited disease severity when treatments were started prophylactically at disease induction or therapeutically after symptoms appear.
  • (2022), Targeting deoxycytidine kinase improves symptoms in mouse models of multiple sclerosis.

Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis

Retrieved on: 
星期二, 八月 30, 2022
Inflammation, ADEM, Cancer, Autoimmune disease, Research, Degenerative disease, Central nervous system, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Brain, Deoxycytidine kinase, Cranial nerves, Death, Multiple sclerosis, DCK, Acute disseminated encephalomyelitis, Mouse, Food, DNA, Orphan drug, GLOBE, Company, FDA, ODS, UCLA, COVID-19, Spinal cord, Marketing, Private Securities Litigation Reform Act, Patient, Pharmaceutical industry

LOS ANGELES, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status (ODS) to TRE-515, Tretheras first-in-class drug for the treatment of acute disseminated encephalomyelitis (ADEM).

Key Points: 
  • LOS ANGELES, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status (ODS) to TRE-515, Tretheras first-in-class drug for the treatment of acute disseminated encephalomyelitis (ADEM).
  • No medications have been specifically approved by the FDA to treat it, said Dr. Peter Clark, a specialist member of the Trethera Scientific Advisory Board.
  • The ODS designation qualifies Trethera for certain incentives, which include FDA assistance in designing clinical trials, access to the FDA Orphan Drug Grants Program, exemption from the drug approval application fee and eligibility for seven years of marketing exclusivity.
  • Trethera's innovative approach to targeting nucleotide metabolism led to the development of TRE-515, an orally taken capsule twice designated by the FDA as an Orphan Drug.

Trethera Receives U.S. Patent Office Notice of Allowance Covering TRE-515 Structural Claims, Extending Protections to Late 2041

Retrieved on: 
星期三, 八月 17, 2022
FDA, GLOBE, Autoimmunity, Private Securities Litigation Reform Act, Cancer, UCLA, Patent, CT, Research, Method, Wilson Sonsini Goodrich & Rosati, United States Patent and Trademark Office, Patient, Deoxycytidine kinase, DNA, Company, Orphan Drug Act of 1983, DCK, COVID-19, Degenerative disease, Multiple sclerosis, USPTO, Pharmaceutical industry

The resulting US patent will extend the patent protection for TRE-515 in the United States by seven years through November 2041.

Key Points: 
  • The resulting US patent will extend the patent protection for TRE-515 in the United States by seven years through November 2041.
  • We are extremely pleased with this expansion of the TRE-515 patent portfolio, said Dr. Ken Schultz, Trethera CEO and patent co-inventor.
  • The patent claims cover the unique TRE-515 chemical structure, whether used in the treatment of cancer, autoimmune, or other diseases.
  • Trethera is currently enrolling patients in a Phase 1 dose escalation trial to evaluate TRE-515 monotherapy in patients with various solid tumors.

Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 for the Treatment of Demyelinating Optic Neuritis

Retrieved on: 
星期二, 八月 9, 2022
FDA, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mouse, Inflammation, CEO, MS, GLOBE, Private Securities Litigation Reform Act, Cancer, UCLA, Optic neuritis, ADEM, Disease, Research, CNS demyelinating autoimmune diseases, Pain, Steroid, Marketing, Patient, Deoxycytidine kinase, DNA, Multiple sclerosis, Company, Orphan drug, Autoimmune disease, Severe cognitive impairment, Central nervous system, ODS, DCK, COVID-19, Optic nerve, Degenerative disease, Food, Immune system, Association, Acute disseminated encephalomyelitis, Pharmaceutical industry, Medical device

LOS ANGELES, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (Trethera), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status (ODS) to TRE-515 for the treatment of optic neuritis (ON).

Key Points: 
  • LOS ANGELES, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (Trethera), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status (ODS) to TRE-515 for the treatment of optic neuritis (ON).
  • TRE-515 is developing an impressive resume for potential treatments of demyelinating autoimmune diseases.
  • The ODS designation qualifies Trethera for certain incentives, which include FDA assistance in designing clinical trials, access to the FDA Orphan Drug Grants Program, exemption from the drug approval application fee and eligibility for seven years of marketing exclusivity.
  • Trethera's innovative approach to targeting nucleotide metabolism led to the development of TRE-515, an orally taken capsule twice designated by the FDA as an Orphan Drug.